Klinikverbund Allgau gGmbH

The Klinikverbund Allgau gGmbH’s hematology department is conducting trials aimed at improving outcomes for patients with blood‑related disorders, particularly myelodysplastic syndrome. Researchers compare new oral agents with standard care to assess safety and the ability to achieve complete remission.

• Oral azacitidine versus placebo in low‑ and intermediate‑risk MDS
• Dose‑finding study of oral azacitidine to define optimal Phase 3 dosing
• Evaluation of event‑free survival in hematologic malignancy cohorts

The site has six investigators overseeing eight active studies, reflecting a strong focus on innovative hematologic therapies.

Clinical research at the oncology unit targets solid tumors, especially various forms of non‑small cell lung cancer and limited‑stage small‑cell lung cancer. Trials test novel targeted drugs, immunotherapies, and peri‑operative regimens to extend survival and increase cure rates.

• Selpercatinib compared with platinum‑pemetrexed ± pembrolizumab in RET‑fusion NSCLC
• Afatinib followed by osimertinib versus osimertinib alone for EGFR‑mutated NSCLC
• Durvalumab combined with chemotherapy before and after surgery for resectable NSCLC

The program leverages eight disease cohorts and emphasizes personalized treatment pathways for patients with advanced or operable lung tumors.

The respiratory research program investigates aggressive lung cancers, focusing on molecular subtypes such as KRAS‑G12C and PD‑L1 negative disease. Studies compare targeted inhibitors with standard immunotherapy to determine the most effective first‑line options.

• Sotorasib plus chemotherapy versus pembrolizumab plus chemotherapy in KRAS‑G12C advanced NSCLC
• Adagrasib alone or with pembrolizumab for KRAS‑mutated NSCLC
• Combination of durvalumab with chemoradiotherapy in limited‑stage small‑cell lung cancer

With eight ongoing trials, the site contributes to advancing therapeutic strategies for challenging respiratory malignancies across Europe.